Literature DB >> 19715910

Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation.

E Rodrigo1, J C Ruiz, M Angeles de Cos, J Ruiz, M Gago, C Piñera, B Sánchez, J González-Cotorruelo, C Gómez-Alamillo, M Arias.   

Abstract

Cyclosporine has a narrow therapeutic window requiring close monitoring to ensure adequate immunosuppression while avoiding nephrotoxicity and other side effects. Pharmacokinetic studies have suggested that cyclosporine levels at 2 hours postdose (C2) is the best single time point to predict area under the concentration curve (AUC) in kidney transplant recipients. C2 also predicted acute rejection episodes and nephrotoxicity better than trough levels (C0). Targeting cyclosporine levels to minimize side effects while maintaining adequate immunosuppressive effects is of clinical interest. There are conflicting evidence and few reports about whether cyclosporine-related side effects are a dose-dependent phenomenon. The aim of this single center study was to ascertain whether cyclosporine side effects were dose-dependent and which single time point level (C0 or C2) was more closely related to them. We analyzed 225 patients on Neoral-based immunosuppression with C0 and C2 levels measured on the same day of 2 different visits. Serum creatinine, glucose, uric acid, potassium, total cholesterol, triglycerides, and 24-hour urinary sodium elimination were measured by routine biochemical analyses. Blood pressure was measured at each visit. A significant positive correlation was observed between C2 and C0 concentrations and levels of potassium (P < .001), total cholesterol (P < .001), systolic blood pressure (P < .001), and pulse pressure (P < .01). There was a significant negative correlation between C2 and uric acid (P < .001). AUCs of receiver operating characteristic (ROC) curves for both C2 and C0 levels were significant as predictors of hyperkalemia (P < .001), hyperuricemia (P = .001), hypercholesterolemia (P < .05), and high systolic blood pressure (P < .05). There were no significant differences between the capacities of C2 or C0 to predict these variables. In conclusion, potassium, total cholesterol, uric acid, and systolic hypertension were influenced by cyclosporine in a dose-dependent manner. Both C2 and C0 were useful to predict cyclosporine side effects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19715910     DOI: 10.1016/j.transproceed.2009.06.155

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  6 in total

1.  Efficacy, Side Effects, and Monitoring of Oral Cyclosporine in Interstitial Cystitis-Bladder Pain Syndrome.

Authors:  Iryna M Crescenze; Barbara Tucky; Jianbo Li; Courtenay Moore; Daniel A Shoskes
Journal:  Urology       Date:  2017-05-18       Impact factor: 2.649

2.  Links between cyclosporin exposure in tissues and graft-versus-host disease in pediatric bone marrow transplantation: analysis by a PBPK model.

Authors:  Cécile Gérard; Nathalie Bleyzac; Pascal Girard; Gilles Freyer; Yves Bertrand; Michel Tod
Journal:  Pharm Res       Date:  2010-10-21       Impact factor: 4.200

3.  Diltiazem as a cyclosporine A-sparing agent in heart transplantation: Benefits beyond dose reduction.

Authors:  Emyal Alyaydin; Holger Reinecke; Izabela Tuleta; Juergen R Sindermann
Journal:  Medicine (Baltimore)       Date:  2022-10-14       Impact factor: 1.817

4.  Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica.

Authors:  Takashi Kageyama; Mika Komori; Katsuichi Miyamoto; Akihiko Ozaki; Toshihiko Suenaga; Ryosuke Takahashi; Susumu Kusunoki; Sadayuki Matsumoto; Takayuki Kondo
Journal:  J Neurol       Date:  2012-10-18       Impact factor: 4.849

5.  Dyslipidemia after kidney transplantation and correlation with cyclosporine level.

Authors:  Mahboobeh-Sadat Hosseini; Zohreh Rostami; Behzad Einollahi
Journal:  Nephrourol Mon       Date:  2013-06-14

6.  Analysis of the variable factors affecting changes in the blood concentration of cyclosporine before and after transfusion of red blood cell concentrate.

Authors:  Masashi Uchida; Natsumi Hanada; Shingo Yamazaki; Hirokazu Takatsuka; Chiaki Imai; Akari Utsumi; Yuki Shiko; Yohei Kawasaki; Takaaki Suzuki; Itsuko Ishii
Journal:  J Pharm Health Care Sci       Date:  2022-02-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.